Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
-
Catheter Cardiovasc Interv · Aug 2021
Multicenter StudyImpact of COVID-19 pandemic on STEMI care: An expanded analysis from the United States.
To evaluate the impact of COVID-19 pandemic migitation measures on of ST-elevation myocardial infarction (STEMI) care. ⋯ The COVID-19 Pandemic has adversely affected many aspects of STEMI care, including timely access to the cardiac catheterization laboratory for PPCI.
-
Catheter Cardiovasc Interv · Dec 2020
Multicenter StudyPercutaneous thrombectomy in patients with massive and very high-risk submassive acute pulmonary embolism.
Examine FlowTriever thrombectomy feasibility in high-risk PE patients. ⋯ Aspiration thrombectomy appears feasible in higher risk acute PE patients with immediate hemodynamic improvement and low in-hospital mortality.
-
Catheter Cardiovasc Interv · Aug 2020
Multicenter StudyPercutaneous Impella RP use for refractory right heart failure in adolescents and young adults-A multicenter U.S. experience.
To assess the outcomes of the use of the percutaneous Impella RP device (Abiomed, Danvers, MA) in adolescents and young adults. ⋯ In this multicenter experience, the Impella RP device was found to be efficacious and safe when used in adolescents and young adults. Further studies are warranted to identify suitable young/pediatric candidates for Impella RP therapy for right heart failure.
-
Catheter Cardiovasc Interv · Jul 2020
Multicenter Study Observational StudyThe impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry.
The prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown. ⋯ CKD is associated with substantial and independent risk for mortality and morbidity at 1-year follow-up in women undergoing TAVR.
-
Catheter Cardiovasc Interv · Mar 2020
Multicenter Study Comparative StudyGender-related differences in patients undergoing transcatheter mitral valve interventions in clinical practice: 1-year results from the German TRAMI registry.
Information on gender-related differences in terms of baseline characteristics and clinical outcome of patients undergoing MitraClip® implantation in daily clinical practice have been studied in smaller populations previously. This study sought to additionally evaluate gender-related differences in a larger German real-world patient population. ⋯ In this analysis from a large prospective, multicenter real-world registry MitraClip® implantation is safe and effective for treatment of significant mitral regurgitation with equal postprocedural results and mortality rates during 1-year follow-up. Men and women showed a persisting and significant clinical benefit at 1-year FU after treatment. Complication and re-intervention rates were low. Additional studies are needed to further evaluate our findings on increased bleeding complications and decreased functional improvement in women at 1-year follow-up after MitraClip® therapy.